BRAF and colorectal carcinoma: V600E mutant BRAF CRC cell lines were resistant to Cetuximab; however, Cetuximab combined with AZ304 decreased cell viability in RKO cells (AZ304, 56.20% ± 4.52 vs. 23.48% ± 2.18, P = 0.0137) and HT-29 cells (AZ304, 54.26% ± 4.23 vs. 29.73% ± 4.06, P = 0.0125).